Dansk doktorgrad fra 2014 viser at stoffskiftesykdommer gir økt risiko for langvarig sykefravær, førtidspensjon og innkomsttap. Merk at studien er gjort på pasienter som altså allerede har en diagnose og får behandling. Likevel har de langt større sjanse for å bli satt på uførepensjon etc sammenlignet med normalpolulasjon

 

Work Disability among people with benign Thyroid Diseases in Denmark. Mette Nexø, 2014

Lenke til artikkel skrevet på bakgrunn av doktorgraden her

Lenker til artikler skrevet om doktorgraden

http://www.dailyrx.com/hyperthyroidism-patients-took-more-sick-leave-and-were-more-likely-be-disability-healthy-peers

http://www.healio.com/endocrinology/thyroid/news/online/%7Bffe5fb14-7914-4eab-9243-8b0ceb1d26d5%7D/thyroid-disease-diagnosis-leads-to-work-absence-disability-in-first-year

http://www.medscape.com/viewarticle/8275970

http://www.eurekalert.org/pub_releases/2014-06/tes-hpm061314.php

Stofskiftesygdomme giver øget risiko for langvarigt sygefravær, førtidspension og indkomsttab

 

Norsk Masteroppgave i helse- og sosialfag fra 2008, Universitetet I Stavanger, Hilde Frafjord

En kvalitativ studie av hvordan unge voksnes med hypothyreose opplever brukermedvirkningen i helsetjenesten

Fra kapittel 4.1.1. (side 46) der brukerne forteller at de stadig går til lege med ulike symptomer, men ikke blir trodd. Blant annet: “Jeg finner meg ikke i at når de sier at når du har hypothyreose og går på medisin, så er du frisk, når jeg kommer og sier at jeg ikke er det “ “ Jeg føler at legen bagatelliserer det. Nå får du behandling og nå skal alt være greit. Men jeg opplever at det ikke er slik, fordi jeg føler at jeg har en del ubehag som er relatert til dette. Og det har stor innvirkning på min hverdag”

 

JA Romijn, JW Smit and SW Lamberts 2003 Department of Endocrinology, Leiden University Medical Center

Intrinsic imperfections of endocrine replacement therapy,

Abstract

Hormonal substitution therapy has been extremely successful, with respect to morbidity and mortality, in the treatment of the major syndromes of endocrine insufficiency. However, many patients treated for endocrine insufficiencies still suffer from more or less vague complaints and a decreased quality of life. It is likely that these complaints are, at least in part, caused by intrinsic imperfections of hormone replacement strategies in mimicking normal hormone secretion. Unfortunately, these complaints are often difficult to assess by clinicometric or biochemical tests, because the effects of hormones in general, and thus of hormone replacement strategies in particular, are difficult to quantify at the tIssue level. Therefore, in clinical practice we rely mostly on plasma variables – ‘plasma endocrinology’ – which are a poor reflection of hormone action at the tIssue level. Appreciation of these intrinsic shortcomings of endocrine therapy is of utmost importance to prevent incorrect labelling of the complaints of many endocrine patients and to achieve further improvement in endocrine replacement strategies.

 

H F Escobar-Morreale, M J Obregón, F Escobar del Rey, and G Morreale de Escobar

Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats.

Abstract We have studied whether, or not, tissue-specific regulatory mechanisms provide normal 3,5,3′-triiodothyronine (T3) concentrations simultaneously in all tissues of a hypothyroid animal receiving thyroxine (T4), an assumption implicit in the replacement therapy of hypothyroid patients with T4 alone. Thyroidectomized rats were infused with placebo or 1 of 10 T4 doses (0.2-8.0 micrograms per 100 grams of body weight per day). Placebo-infused intact rats served as controls. Plasma and 10 tissues were obtained after 12-13 d of infusion. Plasma thyrotropin and plasma and tissue T4 and T3 were determined by RIA. Iodothyronine-deiodinase activities were assayed using cerebral cortex, liver, and lung. No single dose of T4 was able to restore normal plasma thyrotropin, T4 and T3, as well as T4 and T3 in all tissues, or at least to restore T3 simultaneously in plasma and all tissues. Moreover, in most tissues, the dose of T4 needed to ensure normal T3 levels resulted in supraphysiological T4 concentrations. Notable exceptions were the cortex, brown adipose tissue, and cerebellum, which maintained T3 homeostasis over a wide range of plasma T4 and T3 levels. Deiodinase activities explained some, but not all, of the tissue-specific and dose related changes in tissue T3 concentrations. In conclusion, euthyroidism is not restored in plasma and all tissues of thyroidectomized rats on T4 alone. These results may well be pertinent to patients on T4 replacement therapy.

Vår anm: Å behandle kun med T4 (Levaxin) fører IKKE til at alle vev får stoffskiftehormoner de trenger. Husk at hver eneste celle i kroppen er avhengig av T3 som er selve energien de bruker for å utføre jobben sin